Targeting interleukin-15 in patients with rheumatoid arthritis: A proof-of-concept study

Arthritis and Rheumatism

Volumn 52, Issue 9, 2005, Pages 2686-2692

  Baslund, Bo ^a   Tvede, Niels ^a   Danneskiold Samsoe, Bente ^b   Larsson, Per ^c   Panayi, Gabriel ^d   Petersen, Joergen ^e   Petersen, Lars J ^e   Beurskens, Frank J M ^f   Schuurman, Janine ^f   Van De Winkel, Jan G J ^f   Parren, Paul W H I ^f   Gracie, J Alastair ^g   Jongbloed, Sarah ^g   Liew, Foo Y ^g   McInnes, Iain B ^g,h  

^a Rigshospitalet   (Denmark)

^b FREDERIKSBERG HOSPITAL   (Denmark)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^d GUY S HOSPITAL   (United Kingdom)

^e Genmab   (Denmark)

^f GENMAB   (Netherlands)

^g UNIVERSITY OF GLASGOW   (United Kingdom)

^h GLASGOW ROYAL INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; CD69 ANTIGEN; CORTICOSTEROID; CYTOKINE; DISEASE MODIFYING ANTIRHEUMATIC DRUG; GAMMA INTERFERON; IMMUNOGLOBULIN F(AB) FRAGMENT; INTERLEUKIN 15; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY HUMAX INTERLEUKIN 15; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; UNCLASSIFIED DRUG;

ANTIGEN EXPRESSION; APHTHOUS STOMATITIS; APOPTOSIS; ARTICLE; CELL COUNT; CELL PROLIFERATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOKINE RELEASE; DISEASE ACTIVITY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG TOLERABILITY; FEVER; FLU LIKE SYNDROME; HUMAN; HUMAN CELL; INJECTION SITE REACTION; MONONUCLEAR CELL; MYALGIA; NATURAL KILLER CELL; PERIPHERAL BLOOD MONONUCLEAR CELL; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PLEIOTROPY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHEUMATOID ARTHRITIS; SYNOVIAL FLUID; SYNOVITIS; T LYMPHOCYTE SUBPOPULATION; TREATMENT OUTCOME; UPPER RESPIRATORY TRACT INFECTION;

ADULT; AGED; ANTIBODIES, MONOCLONAL; APOPTOSIS; ARTHRITIS, RHEUMATOID; CELL DEATH; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; FEASIBILITY STUDIES; HUMANS; INJECTIONS, SUBCUTANEOUS; INTERFERON TYPE II; INTERLEUKIN-15; KILLER CELLS, NATURAL; LEUKOCYTES, MONONUCLEAR; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; SYNOVIAL FLUID; T-LYMPHOCYTE SUBSETS; TREATMENT OUTCOME;

EID: 25444519432     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.21249     Document Type: Article

References (31)

1. Felson DT, Anderson JJ, Boers M, Bombardier C, Furst D, Goldsmith C, et al. American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995;38:727-35.
2. Maini RN, Taylor PC. Anti-cytokine therapy for rheumatoid arthritis [review]. Annu Rev Med 2000;51:207-29.
3. Lipsky PE, van der Heijde DM, St Clair EW, Furst DE, Breedveld FC, Kalden JR, et al, for the Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. Infliximab and methotrexate in the treatment of rheumatoid arthritis. N Engl J Med 2000;343:1594-602.
4. Bathon JM, Martin RW, Fleischmann RM, Tesser JR, Schiff MH, Keystone EC, et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis [published errata in N Engl J Med 2001;344:240; N Engl J Med 2001;344:76]. N Engl J Med 2000;343:1586-93.
5. Grabstein KH, Eisenman J, Shanebeck K, Rauch C, Srinivasan S, Fung V, et al. Cloning of a T cell growth factor that interacts with the β chain of the interleukin-2 receptor. Science 1994;264:965-8.
6. Bamford RN, Grant AJ, Burton JD, Peters C, Kurys G, Goldman CK, et al. The interleukin (IL) 2 receptor β chain is shared by IL-2 and a cytokine, provisionally designated IL-T, that stimulates T-cell proliferation and the induction of lymphokine-activated killer cells. Proc Natl Acad Sci U S A 1994;91:4940-4.
7. Giri JG, Kumaki S, Ahdieh M, Friend DJ, Loomis A, Shanebeck K, et al. Identification and cloning of a novel IL-15 binding protein that is structurally related to the α chain of the IL-2 receptor. EMBO J 1995;14:3654-63.
8. Dubois S, Mariner J, Waldmann TA, Tagaya Y. IL-15Rα recycles and presents IL-15 in trans to neighboring cells. Immunity 2002;17:537-47.
9. Waldmann TA, Tagaya Y. The multifaceted regulation of interleukin-15 expression and the role of this cytokine in NK cell differentiation and host response to intracellular pathogens [review]. Annu Rev Immunol 1999;17:19-49.
10. Zhang X, Sun S, Hwang I, Tough DF, Sprent J. Potent and selective stimulation of memory-phenotype CD8+ cells in vivo by IL-15. Immunity 1998;8:591-9.
11. Lodolce JP, Boone DL, Chai S, Swain RE, Dassopoulos T, Trettin S, et al. IL-15 receptor maintains lymphoid homeostasis by supporting lymphocyte homing and proliferation. Immunity 1998;9:669-76.
12. Fehniger TA, Suzuki K, Ponnappan A, van Deusen JB, Cooper MA, Florea SM, et al. Fatal leukemia in interleukin 15 transgenic mice follows early expansions in natural killer and memory phenotype CD8+ T cells. J Exp Med 2001;193:219-31.
13. Kennedy MK, Glaccum M, Brown SN, Butz EA, Viney JL, Embers M, et al. Reversible defects in natural killer and memory CD8 T cell lineages in interleukin 15-deficient mice. J Exp Med 2000;191:771-80.
14. McInnes IB, al-Mughales J, Field M, Leung BP, Huang FP, Dixon R, et al. The role of interleukin-15 in T-cell migration and activation in rheumatoid arthritis. Nat Med 1996;2:175-82.
15. McInnes IB, Leung BP, Sturrock RD, Field M, Liew FY. Interleukin-15 mediates T cell-dependent regulation of tumor necrosis factor-α production in rheumatoid arthritis. Nat Med 1997;3:189-95.
16. Kotake S, Schumacher HR Jr, Yarboro CH, Arayssi TK, Pando JA, Kanik KS, et al. In vivo gene expression of type 1 and type 2 cytokines in synovial tissues from patients in early stages of rheumatoid, reactive, and undifferentiated arthritis. Proc Assoc Am Physicians 1997;109:286-301.
17. Thurkow EW, van der Heijden IM, Breedveld FC, Smeets TJ, Daha MR, Kluin PM, et al. Increased expression of IL-15 in the synovium of patients with rheumatoid arthritis compared with patients with Yersinia-induced arthritis and osteoarthritis. J Pathol 1997;181:444-50.
18. Oppenheimer-Marks N, Brezinschek RI, Mohamadzadeh M, Vita R, Lipsky PE. Interleukin 15 is produced by endothelial cells and increases the transendothelial migration of T cells in vitro and in the SCID mouse-human rheumatoid arthritis model in vivo. J Clin Invest 1998;101:1261-72.
19. Harada S, Yamamura M, Okamoto H, Morita Y, Kawashima M, Aita T, et al. Production of interleukin-7 and interleukin-15 by fibroblast-like synoviocytes from patients with rheumatoid arthritis. Arthritis Rheum 1999;42:1508-16.
20. Gonzalez-Alvaro I, Ortiz AM, Garcia-Vicuna R, Balsa A, Pascual-Salcedo D, Laffon A. Increased serum levels of interleukin-15 in rheumatoid arthritis with long- term disease. Clin Exp Rheumatol 2003;21:639-42.
21. Ziolkowska M, Koc A, Luszczykiewicz G, Ksiezopolska-Pietrzak K, Klimczak E, Chwalinska-Sadowska H, et al. High levels of IL-17 in rheumatoid arthritis patients: IL-15 triggers in vitro IL-17 production via cyclosporin A-sensitive mechanism. J Immunol 2000;164:2832-8.
22. Cho ML, Yoon CH, Hwang SY, Park MK, Min SY, Lee SH, et al. Effector function of type II collagen-stimulated T cells from rheumatoid arthritis patients: cross-talk between T cells and synovial fibroblasts. Arthritis Rheum 2004;50:776-84.
23. Brennan FM, Hayes AL, Ciesielski CJ, Green P, Foxwell BM, Feldmann M. Evidence that rheumatoid arthritis synovial T cells are similar to cytokine-activated T cells: involvement of phosphatidylinositol 3-kinase and nuclear factor κB pathways in tumor necrosis factor α production in rheumatoid arthritis. Arthritis Rheum 2002;46:31-41.
24. Groh V, Bruhl A, El-Gabalawy H, Nelson JL, Spies T. Stimulation of T cell autoreactivity by anomalous expression of NKG2D and its MIC ligands in rheumatoid arthritis. Proc Natl Acad Sci U S A 2003;100:9452-7.
25. Ruchatz H, Leung BP, Wei XQ, McInnes IB, Liew FY. Soluble IL-15 receptor α-chain administration prevents raurine collagen-induced arthritis: a role for IL-15 in development of antigen-induced immunopathology. J Immunol 1998;160:5654-60.
26. Fishwild DM, O'Donnell SL, Bengoechea T, Hudson DV, Harding F, Bernhard SL, et al. High-avidity human IgGκ monoclonal antibodies from a novel strain of minilocus transgenic mice. Nat Biotechnol 1996;14:845-51.
27. Villadsen LS, Schuurman J, Beurskens F, Dam TN, Dagnaes-Hansen F, Skov L, et al. Resolution of psoriasis upon blockade of IL-15 biological activity in a xenograft mouse model. J Clin Invest 2003;112:1571-80.
28. Gracie JA, Forsey RJ, Chan WL, Gilmour A, Leung BP, Greer MR, et al. A proinflammatory role for IL-18 in rheumatoid arthritis. J Clin Invest 1999;104:1393-401.
29. Fries JF, Spitz PW, Kraines RG, Holman HR. Measurement of patient outcome in arthritis. Arthritis Rheum 1980;23:137-45.
30. Ortiz AM, Laffon A, Gonzalez-Alvaro I. CD69 expression on lymphocytes and interleukin-15 levels in synovial fluids from different inflammatory arthropathies. Rheumatol Int 2002;21:182-8.
31. Genovese MC, Cohen S, Moreland L, Lium D, Robbins S, Newmark R, et al, for the 20000223 Study Group. Combination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexate. Arthritis Rheum 2004;50:1412-9.